The Conversation (0)
Moleculin Biotech engaged a contract research organization Bioscience, to prepare for a proof-of-concept clinical trial in Poland to study its drug candidate WP1220 for the treatment of cutaneous T-cell lymphoma.
Moleculin Biotech (NASDAQ:MBRX) engaged a contract research organization Bioscience, to prepare for a proof-of-concept clinical trial in Poland to study its drug candidate WP1220 for the treatment of cutaneous T-cell lymphoma.
As quoted in the press release:
“We believe we are in a position to move quickly to develop WP1220,” commented Walter Klemp, Chairman and CEO of Moleculin. “We have a complete IND-enabling data package already, so we should be able to make application soon to the Polish regulatory authorities for a clinical trial authorization. In this case, we believe a proof-of-concept trial in Poland can be completed sooner and for less investment than in the US, giving us a very efficient means to develop yet another asset in our portfolio. As well, success with this trial could help us position WP1220 for accelerated approval in the US.”
CTCL is a rare life-threatening skin cancer with limited treatment options. Pre-clinical studies have suggested that some CTCL cell lines may be particularly sensitive to inhibition of the activated form of STAT3, something for which the Company believes WP1220 is especially well suited.
Click here to read the full press release.
Source: www.marketwired.com
